Aspira Womens Health Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AWH Nasdaq 2835 https://aspirawh.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aspira Womens Health Inc

Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights - Jan 9th, 2023 9:05 pm
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses - Jan 6th, 2023 1:00 pm
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio - Dec 27th, 2022 1:00 pm
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM) - Nov 29th, 2022 9:01 pm
Aspira Women’s Health Reports Third Quarter 2022 Financial Results - Nov 10th, 2022 12:00 pm
Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10 - Nov 1st, 2022 12:00 pm
Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022 - Oct 6th, 2022 8:05 pm
Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference - Oct 5th, 2022 12:00 pm
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women - Sep 12th, 2022 8:28 pm
Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering - Aug 23rd, 2022 12:00 pm
Aspira Women’s Health Inc. Announces Proposed Public Offering - Aug 22nd, 2022 8:02 pm
Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay - Aug 18th, 2022 8:05 pm
Aspira Women’s Health Reports Second Quarter 2022 Financial Results - Aug 10th, 2022 11:30 am
Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10 - Aug 1st, 2022 12:00 pm
Aspira Women's Health (NASDAQ:AWH) adds US$31m to market cap in the past 7 days, though investors from a year ago are still down 81% - Jul 11th, 2022 10:26 am
Aspira Women’s Health Announces Appointment of Two New Board Members - Jun 23rd, 2022 8:05 pm
Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer - Jun 16th, 2022 8:01 pm
Does Aspira Women's Health (NASDAQ:AWH) Have A Healthy Balance Sheet? - May 18th, 2022 11:31 am
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 - May 16th, 2022 5:20 pm
Aspira Women’s Health to Participate in the Upcoming Investor Conferences - May 12th, 2022 8:01 pm